rxrgb Antibody

What is RXRG and how does it function in cellular systems?

RXRG (Retinoid X Receptor Gamma) is a nuclear receptor for retinoic acid that acts as a transcription factor. It functions by forming homodimers or heterodimers with other nuclear receptors to regulate gene expression in response to their ligands, all-trans or 9-cis retinoic acid, and participates in various biological processes . The protein has a calculated molecular weight of 51 kDa, though it is typically observed at 51-55 kDa in experimental systems . RXRG localizes in the nucleus where it can bind to retinoic acid response elements (RARE) to modulate transcriptional activity .

What are the validated applications for RXRG antibodies?

RXRG antibodies have been validated for multiple experimental applications based on research needs:

Positive WB detection has been confirmed in Jurkat cells and mouse ovary tissue, while positive IHC detection has been verified in rat eye tissue and mouse skeletal muscle tissue .

How should researchers distinguish between monoclonal and polyclonal RXRG antibodies for their experiments?

The choice between monoclonal and polyclonal RXRG antibodies depends on the experimental requirements:

• Polyclonal antibodies (e.g., 11129-1-AP): These antibodies recognize multiple epitopes on the antigen, potentially offering higher sensitivity but possibly more background. They are particularly useful for detecting proteins expressed at low levels or when protein conformation might be altered .

• Monoclonal antibodies (e.g., PCRP-RXRG-5C9): These recognize a single epitope, providing higher specificity but potentially lower sensitivity. They are ideal for applications requiring consistent results across experiments, minimal batch-to-batch variation, and long-term studies .

For reproducibility in quantitative experiments, monoclonal antibodies generally offer more consistency, while polyclonal antibodies may be preferable for initial protein detection or when working with denatured proteins.

How can I optimize antigen retrieval methods for RXRG detection in fixed tissue samples?

Optimizing antigen retrieval for RXRG detection requires careful consideration of fixation effects on epitope accessibility. For antibody 11129-1-AP:

• Primary recommendation: TE buffer pH 9.0

• Alternative approach: Citrate buffer pH 6.0

The optimization process should include:

• Time-course experiments: Test retrieval times from 10-30 minutes

• Temperature assessment: Compare boiling vs. sub-boiling temperatures

• Buffer comparison: Directly compare TE buffer (pH 9.0) with citrate buffer (pH 6.0)

• Fixation variables: Adjust protocols based on fixation duration and fixative concentration

• Tissue-specific modifications: Different tissues may require adjusted protocols (e.g., eye tissue vs. skeletal muscle)

A systematic approach testing these variables with proper positive controls (rat eye tissue, mouse skeletal muscle) is essential for optimizing signal-to-noise ratio in RXRG detection.

What are the critical considerations for validating RXRG antibody specificity?

Validating RXRG antibody specificity requires a multi-faceted approach:

• Positive control selection: Use verified RXRG-expressing samples:

  • Jurkat cells

  • Mouse ovary tissue

  • Rat eye tissue

  • Mouse skeletal muscle tissue

• Western blot validation: Confirm a single band at the expected molecular weight (51-55 kDa)

• Knockout/knockdown controls: Compare staining between wild-type and RXRG-deficient samples

• Cross-reactivity assessment: Test against related RXR family members (RXRA, RXRB) to ensure specificity

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Multiple antibody validation: Compare staining patterns using antibodies targeting different epitopes (e.g., compare 11129-1-AP with PCRP-RXRG-5C9)

• Species cross-reactivity verification: If using across species, verify specificity in each species separately

How do dilution optimizations differ for various experimental applications with RXRG antibodies?

Dilution optimization is application-specific and requires systematic titration:

For rabbit polyclonal antibodies like 11129-1-AP, higher affinity generally allows use at lower concentrations (0.2-0.5 μg/ml for IF/IHC and 20-50 ng/ml for WB) .

"The optimal Ig concentration for an application varies by species and antibody affinity. For each product, the antibody titer must be optimized for every application by the end user laboratory."

What methodological approaches can address potential cross-reactivity with other RXR family members?

Cross-reactivity with related RXR family members (RXRA, RXRB) presents a significant challenge when studying RXRG. Researchers should employ the following methodological approaches:

• Epitope mapping: Determine whether the antibody targets conserved or unique regions of RXRG

• Recombinant protein controls: Test antibody reactivity against purified RXRA, RXRB, and RXRG proteins

• Competitive binding assays: Perform pre-absorption with related RXR proteins

• Immunodepletion approach: Sequential immunoprecipitation to remove cross-reactive species

• Genetic verification: Compare results in RXRG-specific knockout models vs. other RXR knockouts

• Data triangulation: Combine protein detection methods with mRNA expression analysis

• Domain-specific antibodies: Select antibodies targeting less conserved regions of RXRG

How does RXRB differ from RXRG, and what are the implications for antibody selection?

RXRB and RXRG belong to the same RXR family but differ in significant ways:

When selecting antibodies for RXR research:

• Epitope consideration: Ensure the antibody targets a region that differentiates between RXR subtypes

• Cross-reactivity testing: Validate against all RXR family members

• Disease context: For autoimmune disease research, consider RXRB-specific antibodies, as RXRB shows significant association (OR = 9.4) with systemic sclerosis through its p.V95A amino acid substitution

• Genetic background: Consider HLA haplotypes when studying RXRB, particularly with HLA-DPB113:01 and DPB109:01

What are the optimal experimental controls when using RXRG antibodies in immunoprecipitation studies?

Robust immunoprecipitation experiments with RXRG antibodies require multiple controls:

• Input control: 5-10% of pre-IP lysate to confirm target presence and enrichment

• Isotype control: Matched concentration of non-specific IgG (e.g., mouse IgG2b for PCRP-RXRG-5C9)

• Bead-only control: Beads without antibody to assess non-specific binding

• Known interactor control: Co-IP a known RXRG binding partner to validate functionality

• Post-IP supernatant analysis: Confirm target depletion from lysate

• Blocking peptide control: Competition with immunizing peptide

• Denaturing conditions control: Compare native vs. denaturing conditions to distinguish direct vs. indirect interactions

For antibodies with LALA mutations (as seen with some therapeutic antibodies), researchers should note these modifications reduce Fc effector function, which may affect certain IP protocols .

How can researchers effectively use RXRG antibodies to study nuclear receptor heterodimerization?

Studying RXRG heterodimerization requires specialized approaches:

• Sequential IP (Re-IP): First IP with RXRG antibody, then with antibody against suspected partner

• Proximity ligation assay (PLA): Detect protein-protein interactions within 40nm using antibodies against both partners

• FRET/BRET analysis: Tag RXRG and partner with appropriate fluorophores/bioluminescent proteins

• Native gel electrophoresis: Preserve complexes before western blotting

• Chromatin immunoprecipitation (ChIP): Assess co-localization at DNA binding sites

• Mammalian two-hybrid system: Verify interactions in cellular context

• Cross-linking protocols: Optimize formaldehyde or DSS cross-linking to capture transient interactions

"Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes."

What recent technological advances enhance RXRG antibody development and applications?

Recent advances in antibody technology with relevance to RXRG research include:

• AI-powered antibody design: The RFdiffusion platform has been fine-tuned to design human-like antibodies with greater precision:

  "In a new preprint, we introduce a version of RFdiffusion fine-tuned to design human-like antibodies... This model produces new antibody blueprints unlike any seen during training that bind user-specified targets."

• Phage display optimization: Advanced techniques similar to those used for developing antibodies like 2C11 and 5C10 (which bind human RGMb with high affinities of 1.4 nM and 0.72 nM)

• Single-chain variable fragments (scFvs): Now being generated using computational approaches:

  "Now, RFdiffusion has been trained to also generate more complete and human-like antibodies called single chain variable fragments (scFvs)."

• Fc modifications: Strategic mutations like LALA (Leu234Ala/Leu235Ala) that modify effector functions without affecting antigen binding

• Experimental validation pipelines: Comprehensive testing frameworks for validating novel antibodies against disease-relevant targets

How can researchers address epitope masking when working with RXRG in different experimental contexts?

Epitope masking presents a significant challenge when detecting RXRG, particularly due to its involvement in protein complexes and chromatin interactions. Methodological approaches include:

• Denaturation optimization:

  • Test graduated SDS concentrations (0.1-2%)

  • Compare heat denaturation temperatures (70°C vs. 95°C)

  • Evaluate reducing agent concentrations

• Fixation alternatives:

  • Compare methanol, paraformaldehyde, and acetone fixation

  • Test dual fixation protocols

  • Assess cross-linker reversal techniques

• Epitope exposure techniques:

  • For IHC: Test both TE buffer pH 9.0 (recommended) and citrate buffer pH 6.0

  • Implement detergent permeabilization gradients

  • Consider protease-assisted epitope retrieval

• Antibody cocktails:

  • Combine antibodies targeting different RXRG epitopes

  • Sequential application of antibodies

• Sample preparation modifications:

  • Nuclear extraction protocols to concentrate target

  • Chromatin shearing optimization

  • Salt extraction techniques

What strategies can resolve inconsistent RXRG detection across tissue types?

Inconsistent RXRG detection across tissues requires a systematic troubleshooting approach:

• Tissue-specific protocol modifications:

  • Skeletal muscle: Extended permeabilization time

  • Eye tissue: Specialized fixation protocols

  • Ovary tissue: Hormone status consideration

• Expression level normalization:

  • Reference tissue calibration curves

  • Quantitative western blot with recombinant standards

  • Multi-tissue validation panels

• Detection system optimization:

  • Amplification systems for low-expression tissues

  • Background reduction for autofluorescent tissues

  • Specialized blocking for high-background tissues

• Fixation adjustments:

  • Fresh-frozen vs. FFPE comparison

  • Post-fixation blocking

  • Duration optimization

• Antibody concentration titration:

  • "It is recommended that this reagent should be titrated in each testing system to obtain optimal results."

  • "Sample-dependent, Check data in validation data gallery."

How can RXRG antibodies contribute to understanding autoimmune disease mechanisms?

While RXRB has established connections to autoimmunity (particularly systemic sclerosis), RXRG's role is increasingly recognized. Research approaches include:

• Comparative expression analysis:

  • Contrast RXRG vs. RXRB expression in affected tissues

  • Correlate with clinical disease parameters

• Therapeutic target assessment:

  • Similar to approaches with anti-RGMb antibodies that "potently inhibited RGMb interaction with PD-L2"

  • Evaluate potential for targeting multiple inhibitory pathways simultaneously

• Genetic association studies:

  • Compare with RXRB findings where "individuals with two factors had elevated risk (P = 6.7 × 10-13; OR = 30.2)"

  • Explore RXRG polymorphisms in patient cohorts

• Chromatin regulation mechanisms:

  • Investigate RXRG's role in chromatin remodeling similar to RXRB

  • Examine epigenetic modifications at RXRG binding sites

• Anti-fibrotic pathway investigation:

  • Extend findings that "RXRB may be involved in antifibrotic activity in skin"

  • Compare with RXRG's tissue-specific effects

What is the potential for RXRG-targeted antibody therapeutics in precision medicine?

The development of RXRG-targeted therapeutics represents an emerging frontier, building on lessons from other antibody development programs:

• Binding affinity optimization:

  • Aim for nanomolar affinities similar to antibodies like 2C11 and 5C10 (1.4 nM and 0.72 nM)

  • Apply AI-driven antibody design techniques as demonstrated with RFdiffusion

• Format diversification:

  • IgG1 backbone options

  • LALA mutations to modify Fc effector functions

  • scFv development using computational approaches

• Target validation pipelines:

  • Expression systems in "ExpiCHO cells"

  • Purification using "protein A column"

  • Functional characterization assays

• Combination therapy potential:

  • Similar to approaches targeting "multiple inhibitory pathways simultaneously to augment anti-tumor immunity"

  • Explore synergies with established checkpoint inhibitors

• Innovative discovery platforms:

  • RFdiffusion for "designing binding proteins with rigid parts"

  • Phage display systems for antibody discovery